News

EMEA may get new pharmacovigilance responsibilities

Country
United Kingdom

The European Medicines Agency (EMEA) will acquire new responsibilities for making sure that drugs launched on the European market are safe under legislation initiated by the European Commission.

Abingworth raises £84 million for life science investment

Country
United Kingdom

The international investment group, Abingworth, has raised an additional £84 million to invest in life science companies, bringing the total funds in its life science vehicle, Abingworth Bioventures V LP, up to £392 million.

MorphoSys announces 3 for 1 stock split

Country
Germany

MorphoSys AG said that it will be offering stockholders three new shares for every one held as part of a previously-authorised stock split. The new shares will trade on the Frankfurt Stock Exchange from 23 December 2008.

Celtic Pharma Holdings seeking early stage investments

Country
United Kingdom

Celtic Pharma Holdings Advisors LLP (CPHA) has launched a new fund that will invest in biotech companies with early stage products at a time when many venture capital companies have shifted their attention to companies with late-stage products.

Bavarian Nordic upgrades revenue forecast for 2008

Country
Denmark

Denmark’s Bavarian Nordic A/S has raised its forecast for revenue in 2008 following higher than expected income from two contracts which it holds with the US National Institutes of Health for the production of a new smallpox vaccine.

Cosmo licences two advanced drug candidates to Santarus

Country
Italy

Cosmo Pharmaceuticals SpA, an Italian company specialising in developing and manufacturing treatments for gastro-intestinal diseases, has licensed two of its advanced drug candidates to Santarus Inc. of the United States in a deal that will leave Cosmo with a 10.5% holding in Santarus and with the possibility of acquiring more shares.